FINAL RESULTS OF THE PYRAMID 1 STUDY, A PHASE 3 REGISTRATIONAL TRIAL OF RAVIDASVIR (PPI-668) AND SOFOSBUVIR IN HCV GENOTYPE-4 PATIENTS: HIGH RATES OF SUSTAINED VIRAL CLEARANCE IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS
Author(s): ,
Gamal Esmat
Affiliations:
Cairo University,Cairo,Egypt
,
Maissa El Raziky
Affiliations:
Cairo University,Cairo,Egypt;,Cairo Fatemic Hospoital,Cairo,Egypt
,
Asmaa Gomaa
Affiliations:
National Liver Institute,Cairo,Egypt
,
Tamer Elbaz
Affiliations:
Cairo University,Cairo,Egypt
,
Mahmoud Abouelkhair
Affiliations:
Cairo University,Cairo,Egypt;,Cairo Fatemic Hospoital,Cairo,Egypt
,
Alyaa Sabry
Affiliations:
National Liver Institute,Cairo,Egypt
,
Hadeel Gamel El Deen
Affiliations:
Cairo University,Cairo,Egypt
,
Mohamed Ashour
Affiliations:
Cairo University,Cairo,Egypt;,Cairo Fatemic Hospoital,Cairo,Egypt
,
Mohammed Abdel-Hamid
Affiliations:
Minia University,Cairo,Egypt
,
Ola Nada
Affiliations:
Ain Shams University,Cairo,Egypt
,
Sherine Helmy
Affiliations:
Pharco Pharmaceuticals,Alexandria,Egypt
,
Hanaa Abdel-Maguid
Affiliations:
Pharco Pharmaceuticals,Alexandria,Egypt
,
Richard Colonno
Affiliations:
Presidio Pharmaceuticals,San Francisco,United States
,
Nathaniel Brown
Affiliations:
Presidio Pharmaceuticals,San Francisco,United States
,
Eric Ruby
Affiliations:
Presidio Pharmaceuticals,San Francisco,United States
,
Pamela Vig
Affiliations:
Presidio Pharmaceuticals,San Francisco,Egypt
Imam Waked
Affiliations:
National Liver Institute,Cairo,Egypt
EASL LiverTree™. Colonno R. Apr 16, 2016; 126017
Topic: Efficacy
Ms. Richard Colonno
Ms. Richard Colonno

Access to Privileged content is an EASL members and LiverTree™ Privileged Users benefit.


Click here to join EASL or renew your membership.

Abstract
Discussion Forum (0)
Rate & Comment (0)
SAT-161

Topic: Hepatitis C - clinical (therapy)

Background and aims
HCV genotype-4 (G4) comprises 90% of HCV infections in Egypt. Recent studies with DAAs have often shown suboptimal rates of sustained virologic response (SVR) in cirrhotic patients. We report a Phase 3 trial of ravidasvir (RDV), a pan-genotypic HCV NS5A inhibitor, plus sofosbuvir (SOF), a nucleotide HCV inhibitor, in 300 Egyptian patients (43% with cirrhosis).

Methods
Patients were 18-65 yr with HCV-G4 infection, HCV RNA >4 log10 IU/mL, without decompensated cirrhosis or other liver disease. Three patient groups were enrolled: interferon (IFN)-naïve non-cirrhotic and cirrhotic, by Fibroscan & FIB-4 score (Group 1); IFN-experienced non-cirrhotic (Group 2); and IFN-experienced cirrhotic (Group 3). Groups 1 and 2 were treated QD with RDV 200 mg + SOF 400 mg for 12 wk, randomized 1:1 to added RBV or no RBV. Group 3 received RDV+SOF+RBV, randomized 1:1 to 12 vs. 16 wk treatment. The primary endpoint is SVR12, defined as non-detectable HCV RNA (<12 IU/mL) by the Abbott Real-Time™ PCR assay at 12 wk post-treatment.

Results
300 patients were enrolled (150 in Group 1, 80 in Group 2, and 70 in Group 3); 170 were non-cirrhotic and 130 (43%) were Childs A cirrhotics. At the time of this abstract all patients have completed treatment-period evaluations, and only 31/300 have not yet completed their SVR12 evaluation. Treatment has been well tolerated, with 1 serious adverse event possibly related to treatment (transient bradycardia). HCV RNA declined rapidly and was undetectable by Wk 8 in all patients. For the 264 patients who have reached their SVR12 evaluation point, 164/164 (100%) non-cirrhotic patients and 94/100 (94%) cirrhotic patients achieved SVR12. There have been no viral breakthroughs. All 6 treatment failures have been post-treatment relapses in cirrhotics receiving 12 wk treatment (1 had only 8 wk). Five patients discontinued unrelated to study treatment.

Conclusions
Overall per protocol, 98% of 264 patients achieved SVR12 with SOF+RDV+/-RBV treatment, with SVR12 in all non-cirrhotic patients and failures limited to 6 relapses in cirrhotic patients. RBV did not improve responses in non-cirrhotics or IFN-naïve cirrhotics. All (100%) 20 patients in Group 3 cirrhotics treated for 16 wk have achieved SVR12 (data pending on another 15), suggesting that 16 wk treatment may be sufficient for optimizing viral clearance in IFN-experienced G4 cirrhotics, the most refractory patients. Final study data will be available at the Congress.

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings